JP2003516393A5 - - Google Patents

Download PDF

Info

Publication number
JP2003516393A5
JP2003516393A5 JP2001543517A JP2001543517A JP2003516393A5 JP 2003516393 A5 JP2003516393 A5 JP 2003516393A5 JP 2001543517 A JP2001543517 A JP 2001543517A JP 2001543517 A JP2001543517 A JP 2001543517A JP 2003516393 A5 JP2003516393 A5 JP 2003516393A5
Authority
JP
Japan
Prior art keywords
oxo
compound
acid
substituted
embedded image
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2001543517A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003516393A (ja
JP5021131B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2000/033260 external-priority patent/WO2001042216A2/en
Publication of JP2003516393A publication Critical patent/JP2003516393A/ja
Publication of JP2003516393A5 publication Critical patent/JP2003516393A5/ja
Application granted granted Critical
Publication of JP5021131B2 publication Critical patent/JP5021131B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2001543517A 1999-12-08 2000-12-08 カスパーゼインヒビターおよびその使用 Expired - Fee Related JP5021131B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16981299P 1999-12-08 1999-12-08
US60/169,812 1999-12-08
PCT/US2000/033260 WO2001042216A2 (en) 1999-12-08 2000-12-08 Caspase inhibitors and uses thereof

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2007315252A Division JP2008101019A (ja) 1999-12-08 2007-12-05 カスパーゼインヒビターおよびその使用
JP2011234386A Division JP2012021032A (ja) 1999-12-08 2011-10-25 カスパーゼインヒビターおよびその使用

Publications (3)

Publication Number Publication Date
JP2003516393A JP2003516393A (ja) 2003-05-13
JP2003516393A5 true JP2003516393A5 (cg-RX-API-DMAC7.html) 2008-01-31
JP5021131B2 JP5021131B2 (ja) 2012-09-05

Family

ID=22617272

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2001543517A Expired - Fee Related JP5021131B2 (ja) 1999-12-08 2000-12-08 カスパーゼインヒビターおよびその使用
JP2007315252A Withdrawn JP2008101019A (ja) 1999-12-08 2007-12-05 カスパーゼインヒビターおよびその使用
JP2011234386A Withdrawn JP2012021032A (ja) 1999-12-08 2011-10-25 カスパーゼインヒビターおよびその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2007315252A Withdrawn JP2008101019A (ja) 1999-12-08 2007-12-05 カスパーゼインヒビターおよびその使用
JP2011234386A Withdrawn JP2012021032A (ja) 1999-12-08 2011-10-25 カスパーゼインヒビターおよびその使用

Country Status (24)

Country Link
US (4) US7517987B2 (cg-RX-API-DMAC7.html)
EP (4) EP2308846A3 (cg-RX-API-DMAC7.html)
JP (3) JP5021131B2 (cg-RX-API-DMAC7.html)
KR (3) KR100904697B1 (cg-RX-API-DMAC7.html)
CN (2) CN100415718C (cg-RX-API-DMAC7.html)
AP (1) AP2002002535A0 (cg-RX-API-DMAC7.html)
AR (1) AR026748A1 (cg-RX-API-DMAC7.html)
AU (3) AU2428301A (cg-RX-API-DMAC7.html)
BR (1) BR0016282A (cg-RX-API-DMAC7.html)
CA (2) CA2393710C (cg-RX-API-DMAC7.html)
CO (1) CO5261609A1 (cg-RX-API-DMAC7.html)
CZ (1) CZ20021970A3 (cg-RX-API-DMAC7.html)
EA (1) EA200200645A1 (cg-RX-API-DMAC7.html)
HU (1) HUP0300782A3 (cg-RX-API-DMAC7.html)
IL (1) IL150077A0 (cg-RX-API-DMAC7.html)
IS (1) IS6411A (cg-RX-API-DMAC7.html)
MX (1) MXPA02005779A (cg-RX-API-DMAC7.html)
NO (2) NO324776B1 (cg-RX-API-DMAC7.html)
NZ (2) NZ519424A (cg-RX-API-DMAC7.html)
PL (1) PL356066A1 (cg-RX-API-DMAC7.html)
SK (1) SK8072002A3 (cg-RX-API-DMAC7.html)
TW (1) TWI275586B (cg-RX-API-DMAC7.html)
WO (1) WO2001042216A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200204390B (cg-RX-API-DMAC7.html)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2369619A1 (en) 1999-04-09 2000-10-19 Cytovia, Inc. Caspase inhibitors and the use thereof
US6723711B2 (en) 1999-05-07 2004-04-20 Texas Biotechnology Corporation Propanoic acid derivatives that inhibit the binding of integrins to their receptors
US6495522B1 (en) 1999-08-27 2002-12-17 Cytovia, Inc. Substituted alpha-hydroxy acid caspase inhibitors and the use thereof
US7230000B1 (en) 1999-10-27 2007-06-12 Cytokinetics, Incorporated Methods and compositions utilizing quinazolinones
US6545004B1 (en) 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
AR026748A1 (es) * 1999-12-08 2003-02-26 Vertex Pharma Un compuesto inhibidor de caspasas, una composicion farmaceutica que lo comprende, un metodo para la sintesis del mismo y un compuesto intermediario paradicha sintesis
PE20011350A1 (es) 2000-05-19 2002-01-15 Vertex Pharma PROFARMACO DE UN INHIBIDOR DE ENZIMA CONVERTIDORA DE INTERLEUCINA-1ß (ICE)
CA2447999C (en) * 2001-05-23 2011-04-26 Vertex Pharmaceuticals Incorporated Caspase inhibitors and uses thereof
US7009049B2 (en) 2002-02-15 2006-03-07 Cytokinetics, Inc. Syntheses of quinazolinones
EP1499898A2 (en) * 2002-04-19 2005-01-26 Vertex Pharmaceuticals Incorporated Regulation of tnf-alpha
AU2003270015A1 (en) 2002-05-09 2003-12-02 Cytokinetics, Inc. Compounds, compositions, and methods
US7166595B2 (en) 2002-05-09 2007-01-23 Cytokinetics, Inc. Compounds, methods and compositions
WO2003103575A2 (en) 2002-05-23 2003-12-18 Cytokinetics, Inc. Compounds, compositions, and methods
CA2489367A1 (en) 2002-06-14 2003-12-24 Cytokinetics, Inc. Compounds, compositions, and methods
PE20040728A1 (es) * 2002-06-28 2004-10-23 Vertex Pharma Inhibidores de caspasa
WO2004009036A2 (en) 2002-07-23 2004-01-29 Cytokinetics, Inc. Compounds compositions and methods
WO2004034972A2 (en) 2002-09-30 2004-04-29 Cytokinetics, Inc. Compounds, compositions, and methods
US7612091B2 (en) * 2002-12-20 2009-11-03 Vertex Pharmaceuticals Incorporated Caspase inhibitors and uses thereof
PE20050159A1 (es) 2003-05-27 2005-04-19 Vertex Pharma Derivados de acido 3-[2-(3-amino-2-oxo-2h-piridin-1-il)-acetilamino]-4-oxo-pentanoico como inhibidores de caspasa
WO2004113305A2 (en) * 2003-06-16 2004-12-29 Vertex Pharmaceuticals Incorporated Diamino substituted quinazoline derivatives as promoters of smn2
EP1692112A4 (en) 2003-12-08 2008-09-24 Cytokinetics Inc COMPOUNDS, COMPOSITIONS, AND METHODS
AU2005223767B2 (en) 2004-03-12 2011-12-01 Vertex Pharmaceuticals Incorporated Processes and intermediates for the preparation of aspartic acetal caspase inhibitors
PL217743B1 (pl) * 2004-05-15 2014-08-29 Vertex Pharma Zastosowanie inhibitorów ICE/kaspazy-1 do leczenia napadów i konwulsji w epilepsji oraz zawierające je kompozycja farmaceutyczna i zestaw
CN1980658A (zh) 2004-05-27 2007-06-13 沃泰克斯药物股份有限公司 治疗自身炎性疾病的ice抑制剂
WO2006057961A1 (en) * 2004-11-24 2006-06-01 Vertex Pharmaceuticals Incorporated 3-[2-(3-acylamino-2-oxo-2h-pyridin-1-yl)-acetylamino]-4-oxo-pentanoic acid derivatives and their use as caspase inhibitors
KR20080038369A (ko) * 2005-07-28 2008-05-06 버텍스 파마슈티칼스 인코포레이티드 카스파제 억제제 프로드럭
EP2001875A2 (en) * 2006-03-08 2008-12-17 Takeda San Diego, Inc. Glucokinase activators
TW200823225A (en) * 2006-11-01 2008-06-01 Astrazeneca Ab New compounds
JP5419706B2 (ja) * 2006-12-20 2014-02-19 タケダ カリフォルニア インコーポレイテッド グルコキナーゼアクチベーター
WO2008116107A2 (en) 2007-03-21 2008-09-25 Takeda San Diego, Inc. Piperazine derivatives as glucokinase activators
EP2288615B1 (en) 2008-05-21 2017-06-21 Genesis Technologies Limited Selective caspase inhibitors and uses thereof
US8518942B2 (en) * 2008-08-06 2013-08-27 Buck Institute For Research On Aging Caspase inhibitors and uses thereof
AU2009298877A1 (en) 2008-09-23 2010-04-08 Georgetown University Viral and fungal inhibitors
US9040715B2 (en) 2008-09-23 2015-05-26 Georgetown University 1,2-benzisothiazolinone and isoindolinone derivatives
US9045524B2 (en) 2009-05-21 2015-06-02 Novagenesis Foundation Selective caspase inhibitors and uses thereof
WO2010138585A1 (en) * 2009-05-29 2010-12-02 Merck Sharp & Dohme Corp. Pyrimidinones as pde10 inhibitors
US8882099B2 (en) 2009-08-25 2014-11-11 Lasermax Roll Systems, Inc. System and method for inline cutting and stacking of sheets for formation of books
WO2011031486A1 (en) 2009-08-25 2011-03-17 Lasermax Roll Systems, Inc. System and method for inline cutting and stacking of sheets for formation of books
US9365612B2 (en) 2010-01-29 2016-06-14 United States Of America As Represented By The Secretary, Department Of Health And Human Services Caspase inhibitors
JP6006908B2 (ja) 2010-11-05 2016-10-12 ブランダイス ユニバーシティBrandeis University Ice阻害化合物およびその使用
EP2699091B1 (en) 2011-03-28 2017-06-21 DeuteRx, LLC 2',6'-dioxo-3'-deutero-piperdin-3-yl-isoindoline compounds
DK2697246T3 (en) 2011-04-15 2018-05-28 Genesis Tech Limited SELECTIVE CYSTEIN PROTEASE INHIBITORS AND USES THEREOF
US9956260B1 (en) 2011-07-22 2018-05-01 The J. David Gladstone Institutes Treatment of HIV-1 infection and AIDS
WO2013025897A1 (en) 2011-08-16 2013-02-21 Georgetown University Methods of treating bacterial infections with 1,2-benzisothiazolinone and isoindolinone derivatives
AU2014205043B2 (en) 2013-01-14 2018-10-04 Deuterx, Llc 3-(5-substituted-4-oxoquinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives
AU2014236597A1 (en) 2013-03-14 2015-09-24 Deuterx, Llc 3-(substituted-4-oxo-quinazolin-3(4H)-yl)-3-deutero-piperidine-2,6-dione derivatives
US9809545B2 (en) 2013-03-27 2017-11-07 Merck Sharp & Dohme Corp. Factor XIa inhibitors
US9809603B1 (en) 2015-08-18 2017-11-07 Deuterx, Llc Deuterium-enriched isoindolinonyl-piperidinonyl conjugates and oxoquinazolin-3(4H)-yl-piperidinonyl conjugates and methods of treating medical disorders using same
CN113354708B (zh) 2017-01-23 2024-05-14 正大天晴药业集团股份有限公司 作为Caspase抑制剂的联环化合物
CN106749045B (zh) * 2017-03-03 2020-02-14 上海交通大学 一种d-氨基酸氧化酶抑制剂及其制法和应用
KR20200067855A (ko) * 2017-10-04 2020-06-12 바텔리 메모리얼 인스티튜트 제노바이오틱(xenobiotic) 대사에 관련되는 효소들을 선택적으로 규명하기 위한 탐침 (probe) 및 이들을 제조하는 방법 및 사용 방법
WO2021183908A1 (en) * 2020-03-13 2021-09-16 The Trustees Of Columbia University In The City Of New York Gpx4 compounds and compositions and methods of treatment using same
CN116113413A (zh) * 2020-08-05 2023-05-12 株式会社Lg化学 胱天蛋白酶抑制剂用于缓解或治疗骨关节炎的用途
KR102670554B1 (ko) * 2022-01-04 2024-05-30 주식회사 이노보테라퓨틱스 캐스파제 저해제로서의 신규한 이소인돌리논 유도체 화합물
CA3268270A1 (en) * 2022-09-26 2024-04-04 Edgewise Therapeutics, Inc. 1,4-DIHYDROQUINAZOLINONE COMPOUNDS AND ASSOCIATED USES
KR20250174911A (ko) 2023-03-27 2025-12-15 엣지와이즈 테라퓨틱스, 인크. 퀴놀리논 아미드 화합물 및 이의 용도
JP7858148B1 (ja) 2023-03-27 2026-05-13 エッジワイズ セラピューティクス, インコーポレイテッド キナゾリンジオン化合物およびその使用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6204261B1 (en) 1995-12-20 2001-03-20 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β Converting enzyme inhibitors
FR2582514B1 (fr) 1985-05-30 1988-02-19 Rhone Poulenc Sante Medicaments a base d'amides, nouveaux amides et leur preparation
CA2129976C (en) 1992-02-21 2002-09-17 Kevin T. Chapman Peptidyl derivatives as inhibitors of interleukin-1.beta. converting enzyme
US5714484A (en) * 1993-12-08 1998-02-03 Prototek, Inc. α-(1,3-dicarbonylenol ether) methyl ketones as cysteine protease inhibitors
US5847135A (en) * 1994-06-17 1998-12-08 Vertex Pharmaceuticals, Incorporated Inhibitors of interleukin-1β converting enzyme
US5756466A (en) * 1994-06-17 1998-05-26 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1β converting enzyme
GB2292149A (en) 1994-08-09 1996-02-14 Ferring Res Ltd Peptide inhibitors of pro-interleukin-1beta converting enzyme
US5618792A (en) * 1994-11-21 1997-04-08 Cortech, Inc. Substituted heterocyclic compounds useful as inhibitors of (serine proteases) human neutrophil elastase
CA2217850A1 (en) * 1995-05-10 1996-11-14 Chirotech Technology Limited Peptide compounds which inhibit metalloproteinase and tnf liberation, and their therapeutic use
US6252076B1 (en) * 1996-05-04 2001-06-26 Yuhan Corporation Process for preparation of pyrimidine derivatives
BR9712987A (pt) * 1996-10-11 2000-04-18 Warner Lambert Co Inibidores de enzima de conversão de interleucina-1beta de sulfonamida
US6063794A (en) * 1996-10-11 2000-05-16 Cor Therapeutics Inc. Selective factor Xa inhibitors
CA2268098A1 (en) * 1996-10-11 1998-04-23 Warner-Lambert Company Aspartate ester inhibitors of interleukin-1.beta. converting enzyme
AU6908398A (en) * 1996-10-28 1998-05-22 Versicor Inc Fused 2,4-pyrimidinedione combinatorial libraries and biologically active fused 2,4-pyramidinediones
RU2263109C2 (ru) 1999-05-07 2005-10-27 Тексэс Байотекнолоджи Копэрейшн ПРОИЗВОДНЫЕ КАРБОНОВЫХ КИСЛОТ (ВАРИАНТЫ), ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И СПОСОБ СЕЛЕКТИВНОГО ИНГИБИРОВАНИЯ СВЯЗЫВАНИЯ α4β1 ИНТЕГРИНА У МЛЕКОПИТАЮЩЕГО
US6972296B2 (en) 1999-05-07 2005-12-06 Encysive Pharmaceuticals Inc. Carboxylic acid derivatives that inhibit the binding of integrins to their receptors
SK288186B6 (sk) * 1999-05-07 2014-05-06 Encysive Pharmaceuticals, Inc. Deriváty kyseliny propiónovej, ktoré inhibujú väzbu integrínov na ich receptory, farmaceutické kompozície s ich obsahom a ich použitie
AR026748A1 (es) * 1999-12-08 2003-02-26 Vertex Pharma Un compuesto inhibidor de caspasas, una composicion farmaceutica que lo comprende, un metodo para la sintesis del mismo y un compuesto intermediario paradicha sintesis
EP1485107A1 (en) * 2002-02-11 2004-12-15 Vertex Pharmaceuticals Incorporated Phospholipids as caspase inhibitor prodrugs
EP1499898A2 (en) * 2002-04-19 2005-01-26 Vertex Pharmaceuticals Incorporated Regulation of tnf-alpha

Similar Documents

Publication Publication Date Title
JP5021131B2 (ja) カスパーゼインヒビターおよびその使用
US7968716B2 (en) Caspase inhibitors and uses thereof
AU2001249619B2 (en) Carbamate caspase inhibitors and uses thereof
JP2010143942A (ja) カスパーゼインヒビターおよびそれらの用途
JP2004509120A (ja) カスパーゼ阻害剤およびそれらの用途
HK1125369A (en) Caspase inhibitors and uses thereof